AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34027291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg daily)
Number of subjects: 105
Study 34027291 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 105
Study 34027296 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia and vitamin B-12 and folate status assessment in women of reproductive age
Number of subjects: 0
Study 34027296 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted NTD prevalence based on RBC folate concentrations
Number of subjects: 0
Study 34027757 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-befriending intervention comprising six visits over three months with training and ongoing supervision.
Number of subjects: 10
Study 34027894 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 141
Study 34027894 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP, unit = 10 mmHg)
Number of subjects: 141
Study 34027998 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrethroid-PBO nets
Number of subjects: 16
Study 34027998 — intervention group
Group type: EXPERIMENTAL
Intervention: unwashed pyrethroid-PBO nets
Number of subjects: 16
Study 34027998 — intervention group
Group type: COMPARATOR
Intervention: washed pyrethroid-PBO nets
Number of subjects: 16
Study 34028393 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 5-strain probiotic blend (Bl-04, Bi-07, HN019, NCFM, Lpc-37) administered once daily for 30 days
Number of subjects: 188
Study 34028393 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 5-strain probiotic blend
Number of subjects: 188
Study 34028627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 398
Study 34028703 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1211
Study 34028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical AKI (KDIGO negative AND NGAL/hepcidin-25 ratio-positive)
Number of subjects: 198
Study 34028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AKI (KDIGO positive AND NGAL/hepcidin-25 ratio-positive)
Number of subjects: 198
Study 34028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical AKI (KDIGO positive AND NGAL/hepcidin-25 ratio-negative)
Number of subjects: 198
Study 34028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical AKI
Number of subjects: 198
Study 34028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AKI
Number of subjects: 198
Study 34028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled subclinical and clinical AKI
Number of subjects: 198
Study 34028812 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 30412
Study 34028812 — intervention group
Group type: COMPARATOR
Intervention: Active treatment
Number of subjects: 30412
Study 34029273 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative pupillometry (QP) measures including percentage pupil constriction (CONQ), minimum pupillary diameter (MIN), and maximum pupillary diameter (MAX)
Number of subjects: 220
Study 34029273 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model including minimum pupillary diameter 3 minutes after morphine administration (MIN3), minimum pupillary diameter normalized to baseline (MIN31), and percentage pupillary constriction after surgery (T4) standardized to baseline (T1) (CONQ41) along with weight-based morphine dose
Number of subjects: 220
Study 34029345 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine assessment through the HeartlineTM mobile application
Number of subjects: 9106
Study 34029377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (oral calcifediol at days 1, 3, and 7; single high dose of oral cholecalciferol at baseline)
Number of subjects: 356
Study 34029377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 356
Study 34029377 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (daily doses for at least 14 days, continued weekly if vitamin D blood levels > 50 ng/mL)
Number of subjects: 356
Study 34029490 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cortisol level after a 1-mg dexamethasone suppression test
Number of subjects: 1048
Study 34029490 — intervention group
Group type: COMPARATOR
Intervention: Cortisol levels
Number of subjects: 1048
Study 34029566 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEis) and angiotensin-receptor blockers (ARBs)
Number of subjects: 0
Study 34029566 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of ACEis and ARBs
Number of subjects: 0
Study 34029994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues
Number of subjects: 0
Study 34029994 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-interferon-α-based therapies
Number of subjects: 0
Study 34029994 — intervention group
Group type: EXPERIMENTAL
Intervention: Host-targeting strategies
Number of subjects: 0
Study 34030162 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approaches to modulate intestinal microbiota (dietary interventions, probiotic administration, fecal microbiota transplantation)
Number of subjects: 0
Study 34030162 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota modulators
Number of subjects: 0
Study 34030162 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34030173 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Sensitization Inventory (CSI) score ≥ 40
Number of subjects: 335
Study 34030173 — intervention group
Group type: COMPARATOR
Intervention: Central Sensitization Inventory (CSI) score < 40
Number of subjects: 335
Study 34030430 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 80
Study 34030430 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 80
Study 34030643 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID
Number of subjects: 97
Study 34030695 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive fibrosing interstitial lung disease (PF-ILD) patients
Number of subjects: 14413
Study 34030698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-sternotomy
Number of subjects: 60
Study 34030698 — intervention group
Group type: COMPARATOR
Intervention: Mini-thoracotomy
Number of subjects: 60
Study 34030698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34030728 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative serum creatinine (sCr) measurement
Number of subjects: 423
Study 34030728 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term kidney function assessment
Number of subjects: 423
Study 34030728 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician survey on sCr measurement
Number of subjects: 423
Study 34030986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin, ethambutol, and rifampin (simultaneous doses in fasting state and with food and pancreatic enzymes)
Number of subjects: 30
Study 34030986 — intervention group
Group type: COMPARATOR
Intervention: Fasting doses of azithromycin, ethambutol, and rifampin
Number of subjects: 30
Study 34031050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment
Number of subjects: 67
Study 34031051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isavuconazonium sulfate (10 mg/kg body weight, maximum 372 mg)
Number of subjects: 46
Study 34031051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isavuconazonium sulfate (10 mg/kg body weight, maximum 372 mg)
Number of subjects: 46
Study 34031134 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP intervention (≥8 contacts)
Number of subjects: 0
Study 34031134 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (usual care)
Number of subjects: 0
Study 34031380 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially attenuated rDEN2Δ30 challenge virus
Number of subjects: 0
Study 34031508 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) of the anterior faucial pillar region
Number of subjects: 30
Study 34031519 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with severe pneumonia
Number of subjects: 61
Study 34031519 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 patients with severe pneumonia
Number of subjects: 61
Study 34031756 — intervention group
Group type: EXPERIMENTAL
Intervention: LY01610 (liposome-encapsulated irinotecan) administered intravenously every 2 weeks, with the first cycle in dose escalation being 3 weeks.
Number of subjects: 24
Study 34031762 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (RAS)
Number of subjects: 371
Study 34031762 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 371
Study 34031762 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 371
Study 34031858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry and capnography monitoring
Number of subjects: 2447
Study 34031858 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pulse oximetry
Number of subjects: 2447
Study 34031871 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 112
Study 34031871 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 112
Study 34032031 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 81
Study 34032031 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation (early intervention)
Number of subjects: 81
Study 34032202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersomnia Severity Index (HSI)
Number of subjects: 158
Study 34032202 — intervention group
Group type: EXPERIMENTAL
Intervention: HSI-S cutoff score
Number of subjects: 158
Study 34032468 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) combined with Clinical Risk Factors (CRFs)
Number of subjects: 1617
Study 34032468 — intervention group
Group type: COMPARATOR
Intervention: Clinical Risk Factors (CRFs) alone
Number of subjects: 1617
Study 34032468 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) alone
Number of subjects: 1617
Study 34032575 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep South IVR System-Supported Active Lifestyle intervention (IVR-automated physical activity-related phone counseling)
Number of subjects: 240
Study 34032575 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 240
Study 34032578 — intervention group
Group type: EXPERIMENTAL
Intervention: My Diabetes Care (MDC) intervention
Number of subjects: 270
Study 34032578 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study 34032893 — intervention group
Group type: EXPERIMENTAL
Intervention: piggyBac-generated EGFR-CAR T cells
Number of subjects: 9
Study 34032932 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive central blood pressure assessment using an oscillometric automated device (Mobil-O-Graph)
Number of subjects: 100
Study 34032932 — intervention group
Group type: COMPARATOR
Intervention: Invasive blood pressure assessment by radial arterial cannulation
Number of subjects: 100
Study 34033120 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 559
Study 34033120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole cream
Number of subjects: 559
Study 34033120 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole solution
Number of subjects: 559
Study 34033178 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention (aerobic exercise program at 60-85% HRR)
Number of subjects: 150
Study 34033178 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (aerobic exercise program at 20-40% HRR)
Number of subjects: 150
Study 34033178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received standard behavioral support and nicotine replacement therapy
Number of subjects: 150
Study 34033266 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray
Number of subjects: 175
Study 34033596 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-up-and-go (TUG) test
Number of subjects: 49
Study 34033803 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-guided intervention to detect atrial fibrillation (AF) using a monitoring device mailed to patients for continuous monitoring for up to 30 days.
Number of subjects: 1000
Study 34033803 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-guided intervention to detect atrial fibrillation (AF) using a monitoring device.
Number of subjects: 1000
Study 34033835 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic older adults
Number of subjects: 515
Study 34033835 — intervention group
Group type: COMPARATOR
Intervention: Amino acids (independent of diabetes status)
Number of subjects: 515
Study 34033835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen handling pathways
Number of subjects: 515
Study 34034272 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (DCNN) for polyp detection
Number of subjects: 42
Study 34034272 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline detection without DCNN)
Number of subjects: 42
Study 34034272 — intervention group
Group type: EXPERIMENTAL
Intervention: DCNN
Number of subjects: 42
Study 34034693 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer co-delivered vocational rehabilitation services
Number of subjects: 46
Study 34034699 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased availability of lower energy main dishes (50%)
Number of subjects: 2091
Study 34034699 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy labelling
Number of subjects: 2091
Study 34034699 — intervention group
Group type: COMPARATOR
Intervention: Baseline availability of lower energy main dishes (10%)
Number of subjects: 2091
Study 34034772 — intervention group
Group type: EXPERIMENTAL
Intervention: Malreduction criteria (TF overlap)
Number of subjects: 46
Study 34034772 — intervention group
Group type: EXPERIMENTAL
Intervention: Malreduction criteria (dime sign)
Number of subjects: 46
Study 34034772 — intervention group
Group type: EXPERIMENTAL
Intervention: Malreduction criteria (tibiotalar tilt)
Number of subjects: 46
Study 34034772 — intervention group
Group type: EXPERIMENTAL
Intervention: Malreduction criteria (TF widening)
Number of subjects: 46
Study 34034772 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory cytokine levels
Number of subjects: 46
Study 34034777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP) in SARS-CoV-2 patients
Number of subjects: 1576
Study 34034777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP) in influenza pneumonia patients
Number of subjects: 1576
Study 34034777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP) in no viral infection patients
Number of subjects: 1576
Study 34034795 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38-targeted chimeric antigen receptor T (CAR-T-38) cells
Number of subjects: 6
Study 34035077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control and blood pressure-lowering therapy
Number of subjects: 11140
Study 34035077 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty status (FI >0.21)
Number of subjects: 11140
Study 34035077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering and BP-lowering treatments
Number of subjects: 11140
Study 34035090 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world clinical care and outcomes of patients with AMI
Number of subjects: 0
Study 34035097 — intervention group
Group type: EXPERIMENTAL
Intervention: WARM Hearts study assessments including medical history, body composition, cognition, frailty status, functional fitness, physical activity levels, nutritional status, quality of life questionnaires, sleep behaviour, resting blood pressure, BP response to moderate-intensity exercise, arterial stiffness, heart rate variability, lipid and novel biomarker profiles, gut microbiota characterization.
Number of subjects: 1000
Study 34035097 — intervention group
Group type: COMPARATOR
Intervention: WARM Hearts study approaches
Number of subjects: 1000
Study 34035103 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach using functional near-infrared spectroscopy (fNIRS), electroencephalography, and heart rate variability via ECG during cognitive tasks (Stroop, N-back, verbal fluency test).
Number of subjects: 0
Study 34035103 — intervention group
Group type: COMPARATOR
Intervention: Multimodal approach (fNIRS, EEG, ECG)
Number of subjects: 0
Study 34035290 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transfer (AFMT)
Number of subjects: 25
Study 34035441 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbe culture from anaerobically preserved tissue combined with metagenome sequencing (MC-MGS)
Number of subjects: 0
Study 34035441 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-based studies with axenic cultures
Number of subjects: 0
Study 34035477 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-treated (E2)
Number of subjects: 24
Study 34035477 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone-treated (P4)
Number of subjects: 24
Study 34035477 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated (steroid-free)
Number of subjects: 24
Study 34035832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (BID)
Number of subjects: 0
Study 34035832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0
Study 34035833 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later, with additional as-needed doses after course 2.
Number of subjects: 0
Study 34035833 — intervention group
Group type: COMPARATOR
Intervention: IFN-alemtuzumab (2 alemtuzumab 12 mg courses after discontinuation of SC IFNB-1a).
Number of subjects: 0
Study 34036177 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) treatment for 4 weeks
Number of subjects: 36
Study 34036177 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) treatment
Number of subjects: 36
Study 34036233 — intervention group
Group type: EXPERIMENTAL
Intervention: 31-gene expression profile (31-GEP) test
Number of subjects: 323
Study 34036233 — intervention group
Group type: EXPERIMENTAL
Intervention: 31-GEP class 2 results
Number of subjects: 323
Study 34036233 — intervention group
Group type: COMPARATOR
Intervention: Patients with stage I-IIA CM and a class 2 result
Number of subjects: 323
Study 34036233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining 31-GEP results and AJCC staging
Number of subjects: 323
Study 34036343 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 24
Study 34036343 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 34036343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 34036426 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with CAD and CKD
Number of subjects: 3352
Study 34036426 — intervention group
Group type: COMPARATOR
Intervention: Men with CAD and CKD
Number of subjects: 3352
Study 34036490 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 20% subcutaneous immune globulin (SCIG; Cuvitru, Ig20Gly)
Number of subjects: 0
Study 34036552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (100 mg/kg once daily, infused in 30 minutes)
Number of subjects: 45
Study 34036560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone
Number of subjects: 307
Study 34036560 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide-dexamethasone
Number of subjects: 307
Study 34037241 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-containing regimens
Number of subjects: 19934
Study 34037715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg (≥40 kg) or 3 mg/kg (<40 kg)
Number of subjects: 44
Study 34037715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 390 mg (≥40 kg) or 9 mg/kg (<40 kg)
Number of subjects: 44
Study 34037715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses)
Number of subjects: 44
Study 34037951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 52
Study 34037951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 34037999 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional iron-deficiency treatment, specific details not available
Number of subjects: 0
Study 34038379 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg 4 times daily for 1 year
Number of subjects: 62
Study 34038379 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone treatment
Number of subjects: 62
Study 34038421 — intervention group
Group type: EXPERIMENTAL
Intervention: P. vivax infection
Number of subjects: 7
Study 34038421 — intervention group
Group type: COMPARATOR
Intervention: P. falciparum infection
Number of subjects: 7
Study 34038556 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Depletion Score (MDS) in PPCCT
Number of subjects: 10077
Study 34038556 — intervention group
Group type: COMPARATOR
Intervention: Serum magnesium alone in PPCCT
Number of subjects: 10077
Study 34038556 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS in NHANES
Number of subjects: 10077
Study 34038556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low magnesium intake in NHANES
Number of subjects: 10077
Study 34038589 — intervention group
Group type: EXPERIMENTAL
Intervention: SM04690
Number of subjects: 5
Study 34038589 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 5
Study 34038699 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bacterial identification
Number of subjects: 0
Study 34038916 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular nerve block
Number of subjects: 70
Study 34038916 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia
Number of subjects: 70
Study 34039015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare and Covered Cheatham-Platinum Stents
Number of subjects: 248